Compare ARQQ & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARQQ | EOLS |
|---|---|---|
| Founded | 2017 | 2012 |
| Country | United Kingdom | United States |
| Employees | 91 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 250.9M | 284.3M |
| IPO Year | N/A | 2018 |
| Metric | ARQQ | EOLS |
|---|---|---|
| Price | $14.51 | $5.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $60.00 | $15.50 |
| AVG Volume (30 Days) | 344.4K | ★ 714.1K |
| Earning Date | 05-21-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1.23 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $297,176,000.00 |
| Revenue This Year | $381.13 | $13.27 |
| Revenue Next Year | $212.00 | $17.62 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 11.61 |
| 52 Week Low | $11.52 | $3.86 |
| 52 Week High | $62.00 | $12.28 |
| Indicator | ARQQ | EOLS |
|---|---|---|
| Relative Strength Index (RSI) | 49.76 | 65.25 |
| Support Level | $11.72 | $4.02 |
| Resistance Level | $17.75 | $7.29 |
| Average True Range (ATR) | 1.20 | 0.24 |
| MACD | 0.16 | 0.12 |
| Stochastic Oscillator | 45.72 | 83.72 |
Arqit Quantum Inc is a cybersecurity company that has pioneered a symmetric key agreement technology that makes the communications links of any networked device or data at rest secure against current and future forms of cyber attack - even an attack from a quantum computer. The company delivers its symmetric key agreement technology via its product SKA-Platform. The firm operates in one segment, that is, the provision of cybersecurity services. The company operates and generates its revenue from UK.
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.